SABS SAB Biotherapeutics, Inc.
Healthcare$3.90+2.36%ClosedMarket Cap: $37.3M
As of 2026-05-25
Analyst Consensus
Consensus
Buy
Target (Consensus)
$9.33
Target (Median)
$10.00
Target Range
$7.00 - $11.00
Upside from current price: 139.2%
Rating Distribution
0 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell
Recent Analyst Ratings
| Date | Firm | Action | Rating | Previous |
|---|---|---|---|---|
| 2026-05-12 | HC Wainwright & Co. | maintain | Buy | Buy |
| 2026-05-11 | Rodman & Renshaw | maintain | Buy | Buy |
| 2026-03-11 | Chardan Capital | maintain | Buy | Buy |
| 2026-03-10 | HC Wainwright & Co. | maintain | Buy | Buy |
| 2025-12-18 | Chardan Capital | maintain | Buy | Buy |
| 2025-11-17 | Chardan Capital | maintain | Buy | Buy |
| 2025-09-19 | Chardan Capital | maintain | Buy | Buy |
| 2025-08-08 | Chardan Capital | maintain | Buy | Buy |
| 2025-07-22 | HC Wainwright & Co. | maintain | Buy | Buy |
Forward Estimates
| Period | EPS Est. | Revenue Est. | # Analysts |
|---|---|---|---|
| Fri Dec 31 | $-0.66 | $50.0K | 5 |
| Sun Dec 31 | $-0.71 | $7.4M | 7 |
| Mon Dec 31 | $-0.51 | $81.6M | 2 |
| Tue Dec 31 | $0.02 | $227.8M | 5 |